Treatment of the chronic myeloid leukemia by Hydrea in the Ho Chi Minh center for hematology and blood transfusion

88 patients with the chronic myeloid leukemia treated with Hydrea during 1/1999 - 12/2000. Most of them admitted to the center for hematology and blood transfusion in the conditions of very high leukocytosis and acute mortality risk due to cerebrovascular obstruction. Patients indicated by high dose of Hydrea in average duration of treatment of 6.5 (1.8 days. The treatment with Hydrea demonstrated that the survival duration of patients was lasted. The drug had fewer side effects. The treatment was not expensive. This is suitable for economic conditions of patients in Vietnam.

Treatment of the chronic myeloid leukemia by autologous stem cells transplantation of peripheral blood

A patient with the chronic myeloid leukemia received the autologous stem cells transplantation of peripheral blood. The results have shown that the patient was responded well with the autograft, the graft grew early as estimation. The patient also responded completely with the treatment by Hydrea. The clinical and hematological signs were stable in the long-term. The complication during transplantation was mild. The total survival duration was 75 months.

Primarily investigation of artherosclerosis in Ho Chi Minh center for Hematology and Blood Transfussion

7/1999 to 7/2000, 201 patients included 97 males and 104 females, were diagnosed and treated for atherosclerosis in vascular disease unit of hematology center. Followed-up by 3D Doppler, their IMT showed better. We hope this treatment may prevent the accidents of cerebral and coronary arteries.